AFN-1252 tosylate
Based on 12 publication(s) in Google Scholar
AFN-1252 (API-1252) tosylate is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 tosylate exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 tosylate exhibits typical MIC90 values of 0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 tosylate is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith.
For research use only. We do not sell to patients.
- CAS No.: 1047981-31-6
- Formula: C29H29N3O6S
- Molecular Weight:547.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) AFN-1252 tosylate
More- Nat Commun. 2016 Oct 5:7:12944. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155732. [Abstract]
- Cell Rep. 2019 Dec 17;29(12):3974-3982.e4. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- J Lipid Res. 2024 Dec;65(12):100693. [Abstract]
- PLoS Pathog. 2020 Oct 30;16(10):e1008529. [Abstract]
- Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02105-18. [Abstract]
- PLoS Genet. 2026 May 27;22(5):e1012165. [Abstract]
- Patent. US20250270197A1.
- University of Washington. 2024.
- bioRxiv. 2023 Jun 30:2023.06.29.547085. [Abstract]
- Patent. US20210017165A1.
All Antibiotic Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 1047981-31-6
-
Molecular Weight 547.62
-
Formula C29H29N3O6S
-
SMILES
O=S(O)(C1=CC=C(C=C1)C)=O.CC2=C(CN(C)C(/C=C/C(C=C3CC4)=CNC3=NC4=O)=O)OC5=CC=CC=C25
-
Synonyms
API-1252 tosylate; Debio 1452 tosylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials. [Abstract]2016 Oct 5:7:12944. PMID: 27703138 -
Phytomedicine
In vitro and in vivo enhancement effect of glabridin on the antibacterial activity of colistin, against multidrug resistant Escherichia coli strains. [Abstract]2024 Jul 25:130:155732. PMID: 38776738 -
Cell Rep
Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments. [Abstract]2019 Dec 17;29(12):3974-3982.e4. PMID: 31851927 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
J Lipid Res
2024 Dec;65(12):100693. PMID: 39505263 -
PLoS Pathog
Triclosan depletes the membrane potential in Pseudomonas aeruginosa biofilms inhibiting aminoglycoside induced adaptive resistance. [Abstract]2020 Oct 30;16(10):e1008529. PMID: 33125434 -
Antimicrob Agents Chemother
A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production. [Abstract]2019 Mar 27;63(4):e02105-18. PMID: 30718253 -
PLoS Genet
FabF and FadM cooperate to recycle fatty acids and rescue ∆plsX lethality in Staphylococcus aureus. [Abstract]2026 May 27;22(5):e1012165. PMID: 42201948 -
-
-
bioRxiv
Elucidating the Impact of Bacterial Lipases, Human Serum Albumin, and FASII Inhibition on the Utilization of Exogenous Fatty Acids by Staphylococcus aureus. [Abstract]2023 Jun 30:2023.06.29.547085. PMID: 37425828 -
Purity & Documentation
References
[1]. Nachum Kaplan, et al. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J Chemother. 2013 Feb;25(1):18-25. [Content Brief]
[2]. Nachum Kaplan,et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012 Nov;56(11):5865-74. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AFN-1252 tosylate Related Classifications
HY-114622 Related Classifications
Powered by Bioz